CJC-1295
A GHRH analog studied for GH axis stimulation and body composition research. Available in two pharmacokinetically distinct forms — no-DAC (short-acting) and DAC (long-acting). Protocols differ significantly between variants.
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to release growth hormone by activating GHRH receptors. It is available in two pharmacokinetically distinct forms that require completely separate protocols: CJC-1295 without DAC (also called Mod-GRF 1-29), which has a short half-life of approximately 30 minutes, and CJC-1295 with DAC, which binds albumin in the bloodstream for a half-life of approximately 6–8 days.
The no-DAC variant is the more commonly used form in physician practice for body composition protocols. Its short half-life allows for pulsatile administration aligned with natural GH rhythms, typically dosed daily in the AM fasted state. The DAC variant produces sustained GH elevation with less frequent dosing, but its prolonged action carries different considerations for GH feedback and IGF-1 elevation.
In physician practice, CJC-1295 no-DAC is almost always paired with Ipamorelin. The combination uses two complementary mechanisms — GHRH receptor stimulation (CJC-1295) and ghrelin receptor stimulation (Ipamorelin) — to produce a synergistic GH pulse that significantly exceeds what either compound achieves alone.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
CJC-1295 is not FDA-approved and is prohibited under WADA. Research use only. Critical: no-DAC and DAC variants are not interchangeable — verify the exact variant before applying any protocol.
Side effects include water retention, joint aches, and transient numbness consistent with GH elevation. Long-term safety in healthy adults not established. All information for educational reference only.